Markets

AIxCrypto Is Turning a Tiny Cancer Biotech Into an AI + Web3 Experiment

Date Published

AIxCrypto Is Turning a Tiny Cancer Biotech Into an AI + Web3 Experiment

TL;DR

Quick Summary

  • AIxCrypto Holdings (AIXC) pivoted from a micro-cap cancer biotech into an AI + Web3 platform after rebranding on November 20, 2025.
  • Its AIxC Hub, launched January 7, 2026, hit 500,000+ wallets and about 200,000 daily active participants within one week via a zero-capital prediction "Arena".
  • On January 6, 2026, AIXC signed a non-binding term sheet to buy $10M of Faraday Future (FFAI) stock as the base for a potential tokenized equity RWA product.
  • A new Web3 license in the UAE, announced December 23, 2025, gives AIXC room to build tokenization, DeFi, and AI–crypto products in a friendlier jurisdiction.
  • The stock, still around the $2 zone as of December 31, 2025, is essentially a live experiment in whether AI, crypto, and listed equities can fuse into a workable business model.

#RealTalk

AIxCrypto is less a finished company and more a public-market sandbox for AI + Web3 experiments, with real users, real regulators, and real execution risk. The upside story is imaginative; the evidence is just beginning to show up in product traction rather than profits.

Bottom Line

For investors watching AIXC, the real signal isn’t short-term price swings, it’s whether AIxC Hub activity stays high and translates into durable products that people actually use. The Faraday Future tokenization plan and the UAE license are early test cases for that vision, not guarantees of success. Anyone paying attention here is effectively tracking a case study in how a tiny, formerly biotech stock tries to reinvent itself as infrastructure for the AI × Web3 era. The narrative is big; the numbers will need time to catch up.

What’s going on with AIxCrypto Holdings

AIxCrypto Holdings, Inc. (AIXC) is having one of the stranger second acts in recent market history. As of December 31, 2025, this was still technically the shell of a tiny cancer drug developer, trading around $2.14 with a market cap near $11 million. By January 2026, it’s being pitched as an "Embodied AI + Web3" platform trying to connect old-school stocks with on-chain finance.

The pivot started in November 2025, when Qualigen Therapeutics officially rebranded as AIxCrypto Holdings and switched its ticker to AIXC on November 20, 2025. Faraday Future Intelligent Electric (FFAI) became the majority owner, controlling roughly 55% of the equity (about 63% including affiliated holders) and steering the company away from clinical trials and into digital infrastructure.

From lab coats to wallets and arenas

Instead of focusing on pancreatic cancer drugs, AIxCrypto now talks about "Embodied AI" and Real World Assets (RWA). In practice, that currently means AIxC Hub, an engagement platform that looks like a mashup of a prediction game, crypto community hub, and behavior-data engine.

AIxC Hub officially launched its first competitive “Arena” season on January 7, 2026. Within the first week, management said the platform crossed 500,000+ registered wallets and around 200,000 daily active participants by January 15, 2026. Users make rapid-fire predictions on the company’s C10 Index of digital assets, updated every 10 seconds, in a zero-capital format where you’re trading points, not cash.

Underneath the game layer, AIxCrypto is very explicit about the real goal: using all those micro-predictions and decisions as training data for its AI models. Millions of calls on market direction turn into behavioral signals that can feed its "DeAI" agents and future products.

The Faraday Future tokenization angle

The other big plotline arrived on January 6, 2026. AIxCrypto signed a non-binding term sheet to buy an initial $10 million tranche of Faraday Future (FFAI) common stock, facilitated through a third party. If they close a definitive agreement, AIxCrypto wants to use those FFAI shares as the base asset for its first tokenized equity RWA product.

In plain English: AIxCrypto is trying to take a traditional Nasdaq stock, wrap it in blockchain infrastructure, and potentially issue a token that reflects that underlying equity. It’s not live yet, and the term sheet is still just that—a term sheet—but it’s a clear signal of where the company wants to go.

Why the UAE suddenly matters

To make any of this work at scale, you need regulators that are at least Web3-curious. On December 23, 2025, AIxCrypto announced it had set up a UAE subsidiary in Ras Al Khaimah Innovation City and secured approval for a Web3 operations license, pending final administrative steps. That license opens the door to building tokenized RWA products, DeFi protocols, and AI–crypto integrations in a jurisdiction that’s actively courting this type of business.

For a company that was a micro-cap biotech 18 months ago, this is a dramatic upgrade in optionality. It doesn’t magically fix the economics, but it gives AIxCrypto a home base to experiment with tokens, DAOs, and cross-border capital flows without constantly tripping legacy U.S. rules.

What this all means for next-gen investors

By January 23, 2026, AIXC is still tiny, still volatile, and still early. The core story isn’t about today’s income statement; it’s about whether three pieces can lock together: a behavior-rich prediction platform (AIxC Hub), tokenized equity experiments (starting with Faraday Future), and a regulatory foothold in the UAE.

If AIxCrypto executes, it effectively becomes a live sandbox for how AI, crypto, and public equities might intersect—using a real Nasdaq-listed entity, not a whitepaper. If it doesn’t, this chapter may just be remembered as one of the more ambitious pivots in small-cap history. 🧩